CAR-T Therapies: Stakeholders Urge Rethinking Of Postmarketing Requirements And REMS

Long-term follow-up requirements have taken a conservative approach, but could be ripe for re-examination and global harmonization, Kite Pharma executive director says, while former FDA gene/cell therapy office head Wilson Bryan wants the classwide REMS eliminated.